Search results

The world's rapidly growing demand for raw manganese has made it increasingly important to develop methods for the economic recovery of manganese from secondary sources. The current study aims to present possible ways for the recycling and reuse of silico-manganese slag landfilled in Tulcea, City on the Danube River close to the Danube Delta Biosphere Reserve in order to save the natural resources raw of manganese. In the last three decades, the ferroalloy production plant has over 2.6 million tons of slag. Slag dumping constitutes a significant source of air, water and soil pollution, which adversely affects the environment and human health. Mn present in the slag dump is an environmental pollutant with potentially toxic effects. The results obtained with a leaching method to recover manganese from slag shows two efficient ways to valorize manganese from solid fraction (54%) with size particles between 80 and 315 µm and/or reuse the leaching medium (56% Mn) with a slag size of < ; 80 µm. The motivation of our research is the possibility to recover manganese from slag by saving natural resources of raw of manganese and the remaining fraction can be used as aggregate sources (construction and road rehabilitation by saving extract mineral aggregates and agriculture), in order to decommission the slag dump. The proposed research is in concordance with the sustainable use of natural resources for the achievement of sustainable development of the 2030 Agenda and Waste Management Legislation due of the huge ecological costs regarding non-conforming waste dumping. If we consider the cost-benefit analysis, the environmental future is more important the human health and the benefits on the quality of the population's health and the environment which are not non-measurable in monetary value.

The University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), in collaboration with the Food and Drug Administration (FDA), conducted research and outreach to solicit input from the public, including medical specialists, to better understand the use of certain bulk drug substances nominated for use in compounding by outsourcing facilities under section 503B of the Federal Food, Drug, and Cosmetic Act (the Act). In particular, we were interested in how drugs compounded with these bulk drug substances were used historically, and how they are currently used in clinical practice. The research will assist the FDA in its development of a list of bulk drug substances that outsourcing facilities can use in compounding under section 503B of the Act. Research for each bulk drug substance included a systematic literature review, interviews with medical experts and a survey of healthcare practitioners. Our findings for the nominated substance, manganese sulfate pentahydrate, were summarized in this report. ; U.S. Food and Drug Administration Clinical use of bulk drug substances nominated for inclusion on the 503B Bulks List Grant number: 5U01FD005946